# IN10018 Combination Therapy in Treatment-naïve ES-SCLC

> **NCT06030258** · PHASE1,PHASE2 · RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** IN10018
- **DRUG:** Tislelizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06030258
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2025-12-24
- **Final completion:** 2025-12-24
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030258, "IN10018 Combination Therapy in Treatment-naïve ES-SCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06030258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*